Extended treatment with typical and atypical antipsychotic drugs: Differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum

Life Sciences

Volumn 69, Issue 11, 2001, Pages 1257-1268

  Dean, Brian ^a,b   Hussain, Tabasum ^a,b   Scarr, Elizabeth ^a   Pavey, Geoffrey ^a   Copolov, David L ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

Antipsychotic drugs; Dopamine receptors; GABAA receptors

Indexed keywords

3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; 4 AMINOBUTYRIC ACID A RECEPTOR; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; EMONAPRIDE; HALOPERIDOL; MUSCIMOL; NEUROLEPTIC AGENT; OLANZAPINE; RADIOLIGAND; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG RECEPTOR BINDING; LIGAND BINDING; MALE; NONHUMAN; PSYCHOSIS; RAT; RECEPTOR DENSITY;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BENZODIAZEPINES; CHLORPROMAZINE; CLOZAPINE; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; MUSCIMOL; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, GABA-A;

EID: 0035800423     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(01)01214-0     Document Type: Article

References (44)

1. Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain
2. Brain neurotransmitter receptors after long-term haloperidol: Dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors
3. Striatal dopamine receptors become supersensitive while rats are given trifluoperazine for six months
4. Dopamine-mediated behaviour and 3H-spiperone binding to striatal membranes in rats after nine months haloperidol administration
5. During one year's neuroleptic treatment in rats striatal dopamine receptor blockade decreases but serum prolactin levels remain elevated
6. Dopamine receptor subtypes: Differential regulation after 8 months treatment with antipsychotic drugs
7. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats
8. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration
9. Chronic continuous administration of neuroleptic drugs alters cerebral dopamine receptors and increases spontaneous dopaminergic action in the striatum
10. Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: Studies with chronic clozapine and haloperidol
11. Effect of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in rat brain
12. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in the rat brain
13. Treatment with haloperidol or clozapine causes changes in dopamine receptors but not adenylate cyclase or protein kinase C in the rat forebrain
14. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum
15. Clozapine: A novel antipsychotic agent
16. Regional brain changes in 3H]SCH 23390 binding to dopamine D1, receptors after long-term haloperidol treatment: Lack of correspondence with the development of vacuous chewing movements
17. D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment
18. Chronic neuroleptic treatment increases D-2 but not D-1 receptors in rat striatum
19. Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors
20. Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats
21. Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors
22. Radio-receptor binding profile of the atypical antipsychotic olanzapine
23. Are animal studies of antipsychotic drugs appropriately dosed? Lessons from bedside to bench
24. A postmortem study of frontal cortical dopamine D1 receptors in schizophrenics, psychiatric controls, and normal controls
25. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia
26. The binding of both [3H]nemonapride and [3H]raclopride are increased in schizophrenia
27. Changes in serotonin2A and GABA(A) receptors in schizophrenia: Studies on the human dorsolateral prefrontal cortex
28. Dopamine receptors in human brain: Autoradiographic distribution of D1 sites
29. Autoradiographic evidence of [3H]SCH 23390 bindin sites in human prefrontal cortex (Brodmann's area 9)
30. Brain σ receptors labelled by [3H]nemonapride
31. [3H]YM-09151-2 (nemonapride), a potent radioligand for both sigma 1 and sigma 2 receptor subtypes
32. Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1- propyl)piperidine
33. Interaction of [3H](-)-SKF-10,047 with brain sigma receptors: Characterization and autoradiographic visualization
34. Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain
35. (1985) Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs
36. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
37. (1998) Receptor mechanisms of antipsychotic drug atypicality
38. The new atypical antipsychotics: A lack of extrapyramidal side- effects and new routes in schizophrenia
39. 1 binding site correlates of haloperidol-induced oral dyskinesias in rat
40. The interaction between GABA and dopamine: Implications for schizophrenia
41. Effects of p-chloroamphetamine on release of [3H]gamma-amino-butyric acid from slices of rat caudate-putamen
42. Muscarinic modulation of striatal dopamine, glutamate and GABA release, as measured with in vivo microdialysis
43. A receptor binding in superficial layers of cingulate cortex in schizophrenia
44. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics